Martine C Morrison
Overview
Explore the profile of Martine C Morrison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inia J, Attema J, de Ruiter C, Menke A, Caspers M, Verschuren L, et al.
FASEB J
. 2024 Oct;
38(20):e70087.
PMID: 39463193
Fibroblast growth factor 21 (FGF21) is a promising target for treatment of obesity-associated diseases including metabolic dysfunction-associated steatohepatitis (MASH) and atherosclerosis. We evaluated the effects of the bispecific anti-FGF21-β klotho...
2.
Seidel F, Vreeken D, Custers E, Wiesmann M, Ozsezen S, van Duyvenvoorde W, et al.
Heliyon
. 2024 Oct;
10(19):e38516.
PMID: 39391513
It is unclear whether early metabolic and inflammatory aberrations in the liver are associated with detrimental changes in brain structure and cognitive function. This cross-sectional study examines putative associations between...
3.
Gonzalez Hernandez M, Verschuren L, Caspers M, Morrison M, Venhorst J, van den Berg J, et al.
Sci Rep
. 2024 Oct;
14(1):23362.
PMID: 39375498
The incidence of MASLD and MASH-associated fibrosis is rapidly increasing worldwide. Drug therapy is hampered by large patient variability and partial representation of human MASH fibrosis in preclinical models. Here,...
4.
Kaufmann L, Custers E, Vreeken D, Snabel J, Morrison M, Kleemann R, et al.
J Affect Disord
. 2024 Jul;
362:174-185.
PMID: 38960334
Background: Depression and obesity are associated with impaired inhibitory control. Behavioral evidence indicates an exacerbating additive effect when both conditions co-occur. However, the underlying neural mechanisms remain unclear. Moreover, systemic...
5.
Spoelder M, Bright Y, Morrison M, van Kempen V, de Groodt L, Begalli M, et al.
Cells
. 2023 Oct;
12(20).
PMID: 37887307
Increased insulin levels may support the development of neural circuits involved in cognition, while chronic mild inflammation may also result in cognitive impairment. This study aimed to gain more insight...
6.
Seidel F, Fluiter K, Kleemann R, Worms N, van Nieuwkoop A, Caspers M, et al.
Front Cell Neurosci
. 2023 Aug;
17:1267913.
PMID: 37614912
[This corrects the article DOI: 10.3389/fncel.2023.1205261.].
7.
Morrison M, Egelandsdal B, Harvei S, Rocha S, Pieterman E, Kleemann R, et al.
FASEB J
. 2023 Jul;
37(8):e23096.
PMID: 37477964
Cardiovascular disease (CVD) is closely associated with obesity through risk factors such as dyslipidemia and chronic low-grade inflammation, which may be affected by diet. Dietary fats have been extensively studied...
8.
Seidel F, Fluiter K, Kleemann R, Worms N, van Nieuwkoop A, Caspers M, et al.
Front Cell Neurosci
. 2023 Jul;
17:1205261.
PMID: 37457817
Introduction: Obesity has been linked to vascular dysfunction, cognitive impairment and neurodegenerative diseases. However, experimental models that recapitulate brain pathology in relation to obesity and vascular dysfunction are still lacking....
9.
Inia J, Stokman G, Morrison M, Worms N, Verschuren L, Caspers M, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37239841
Semaglutide, a glucagon-like peptide-1 receptor agonist, is an antidiabetic medication that has recently been approved for the treatment of obesity as well. Semaglutide is postulated to be a promising candidate...
10.
Inia J, Stokman G, Pieterman E, Morrison M, Menke A, Verschuren L, et al.
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175538
Patients with metabolic syndrome are often prescribed statins to prevent the development of cardiovascular disease. Conversely, data on their effects on non-alcoholic steatohepatitis (NASH) are lacking. We evaluated these effects...